stars 1 stars 2 stars 3

Bioxodes is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of therapeutics for patients with thrombo-inflammatory diseases. We leverage our deep understanding of the thrombotic and inflammatory processes to design novel product candidates with an aim to address unmet medical needs.

Bioxodes Questions

The Bioxodes annual revenue was $1 million in 2026.

Marc Dechamps is the CEO of Bioxodes.

8 people are employed at Bioxodes.

The NAICS codes for Bioxodes are [325, 32541, 32, 3254].

The SIC codes for Bioxodes are [283, 28].

Top Bioxodes Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users